ALTUVIIIO
Aug 22, 2025
Hemophilia A Beyond Standard Factor Therapies: Can Gene Therapy, anti-TFPI, and siRNA Siege HEMLIBRA and ALTUVIIIO’s Throne?
Over the past four decades, hemophilia A treatment has advanced remarkably. Beginning with the introduction of cryoprecipitate in 1964, treatment progressed to plasma-derived FVIII, then to recombinant FVIII therapies in the 1980s. The 1990s and 2000s saw the rise of Standard Half-life (SHL) products, followed by E...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
